NEW YORK (November 22, 2019) -- The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.
AMP PD is a public-private partnership between the The Michael J. Fox Foundation for Parkinson’s Research, National Institutes of Health, the U.S. Food and Drug Administration, with industry (Celgene, GSK, Pfizer, Sanofi and Verily) and managed through the Foundation of the National Institutes of Health (FNIH). The goal of this partnership is to transform and accelerate drug development in PD by providing the expertise and support needed to determine which biomarkers show the greatest potential for predicting PD and the progression of the disease.
“AMP PD is a true example of the whole being greater than the sum of its parts,” said Walter Koroshetz, M.D., director, National Institute of Neurological Disorders and Stroke (NINDS). “The combination of many data sets could allow researchers greater power to analyze potential biomarkers for Parkinson’s disease. This effort follows other AMP programs which have the shared goal of changing the way we go about the business of studying disease.”
The AMP PD Knowledge Portal contains data from cerebrospinal fluid, RNA, plasma and DNA samples previously collected through programs including MJFF and National Institute of Neurological Disorders and Stroke (NINDS) BioFIND Study, the Harvard Biomarkers Study of Brigham and Women's Hospital and Massachusetts General Hospital, the NINDS Parkinson's Disease Biomarkers Program, and MJFF’s Parkinson’s Progression Markers Initiative. Additionally, AMP PD provides a platform that can incorporate additional data sources and new types of data, including proteomics, a project already planned.
“One important part of this platform is that, in addition to providing a place for storing complex data, we are also providing the tools to analyze that data within the platform itself,” said Debra Babcock, M.D., Ph.D., program director at NINDS and co-chair of the AMP PD Steering Committee. “In this way, we are bringing scientists to the data, which will increase opportunities for collaboration.”
Over the past 18 months, AMP PD scientific teams have worked to ensure that the data added into the portal was accurate and described in a consistent way. This crucial step, called data harmonization, allows information gathered from different programs to be compared, and it also provides best practices for how to integrate new data provided by the community into the platform. One of the unique features of these data is that they are longitudinal – it will allow researchers to analyze data from across an individual’s lifespan or disease course.
Through a single data use agreement, researchers can today apply for access to the knowledge portal and interact with the entire data set here.
“The AMP model has provided a unique platform for bringing together diverse patient cohorts, advances in technology and scientific expertise to study Parkinson’s disease on a scale that has not been attempted before,” said David Wholley, Senior Vice President, Research Partnerships, FNIH. “With the AMP PD Knowledge Portal, we are helping the scientific community worldwide to fast-track discoveries that we hope will ultimately help Parkinson’s disease patients and their families.”